These data are part of a New Drug Application that has been granted priority review by the U.S. Food and Drug Administration PRINCETON, N.J., June 3, 2022 — Taiho Oncology, …
Topic:
cholangiocarcinoma
-
-
U.S. Food and Drug Administration (FDA) Accepts for Priority Review Taiho Oncology’s New Drug Application for Futibatinib for Cholangiocarcinoma
by Your NewsEach year, approximately 8,000 individuals in the U.S. are diagnosed with CCA,1 a rare cancer of the bile ducts of the liver, and approximately 0.3-6 people per 100,000 individuals live …